Skip to main content

Immunogen Inc(IMGN-Q)
NASDAQ

Today's Change
Delayed Last Update

On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

PR Newswire - Wed Sep 20, 2023

FN Media Group Presents USA News Group News Commentary

VANCOUVER, British Columbia , Sept. 20, 2023 /PRNewswire/ -- USA News Group - Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their  "Cancer Moonshot" initiative, an ambitious plan to slash cancer rates in half within the next quarter-century. Already, 2023 is brimming with encouraging progress in the biotech sector that is boosting our hope in the battle against cancer. Simplifying the jargon, this includes major breakthroughs in treatments that are prolonging the time before cancer worsens (known as progression-free survival or PFS) and increasing the rate at which patients respond positively to treatment (overall response rate or ORR). This inspiring progress has been led by companies like from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company, ImmunoGen, Inc. (NASDAQ: IMGN), Merck &Co., Inc. (NYSE: MRK), and AstraZeneca PLC (NASDAQ: AZN).

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe